Every material Form 8-K Xilio Therapeutics, Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xilio Therapeutics reported second quarter 2026 results, with collaboration and license revenue rising to $18.7 million from $8.1 million a year earlier and the net loss narrowing to $6.4 million from $15.8 million. The company also said the FDA cleared its IND application for XTX501, and it expects existing cash to fund operations into the first quarter of 2028.
Collaboration and license revenue was $18.7 million for the quarter ended June 30, 2026, compared with $8.1 million a year earlier, driven by agreements with AbbVie and Gilead.
Net loss was $6.4 million, compared with $15.8 million for the same quarter of 2025.
The FDA cleared the IND application for XTX501 to proceed to a Phase 1/2 trial; dosing in the Phase 1 portion is expected in the second half of 2026.
Cash and cash equivalents were $136.0 million as of June 30, 2026, with runway expected into the first quarter of 2028.
At its June 10, 2026 annual meeting, Xilio Therapeutics stockholders re-elected four Class II directors and approved an amended and restated 2021 Stock Incentive Plan. Director Daniel Curran moved from Class II to Class III so each class now has three directors, with no change to his compensation.
June 10, 2026: annual meeting; stockholders re-elected Akintunde Bello, Daniel Curran, Robert Ross and Yuan Xu as Class II directors
Daniel Curran resigned as a Class II director and was re-appointed as a Class III director, with a term ending at the 2027 annual meeting
Stockholders approved the amended 2021 plan with 3,424,710 votes for and 355,015 against; the plan counts prefunded warrant shares in the annual evergreen increase
Stockholders ratified Ernst & Young LLP as auditor for fiscal 2026 with 5,047,290 votes for and 11,876 against
Xilio Therapeutics reported first quarter 2026 results, with collaboration and license revenue of $12.6 million, up from $2.9 million a year earlier, and a net loss of $9.5 million, down from $13.3 million. Net loss per share improved to $0.58 from $2.49, and the company said its cash runway now extends into early 2028.
Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, versus $2.9 million a year earlier, mainly from AbbVie and Gilead agreements.
R&D expenses rose to $19.8 million from $8.3 million, while G&A expenses fell to $6.9 million from $8.5 million.
Cash and cash equivalents were $150.3 million at March 31, 2026, versus $137.5 million at December 31, 2025, after $37.3 million in net proceeds from a February 2026 follow-on offering.
Xilio achieved a $6.0 million development milestone under the AbbVie collaboration in the second quarter of 2026 and plans to submit an XTX501 IND application in mid-2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xilio Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →